CASI Pharmaceuticals (CASI) Earning Somewhat Positive Media Coverage, Report Shows
Media stories about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.9600820297213 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Head-To-Head Review: CASI Pharmaceuticals (CASI) & Its Rivals (americanbankingnews.com)
- CASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per Share (americanbankingnews.com)
- Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 173,500 Shares of Stock (americanbankingnews.com)
- CASI Pharmaceuticals, Inc. (CASI) Director Wei-Wu He Purchases 207,502 Shares (americanbankingnews.com)
- CASI Pharmaceuticals, Inc. (CASI) Director Buys $419,384.91 in Stock (americanbankingnews.com)
CASI has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Maxim Group restated a “buy” rating and issued a $4.00 price target on shares of CASI Pharmaceuticals in a research note on Friday, September 8th. Finally, ValuEngine upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 15th.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01).
In other CASI Pharmaceuticals news, Director Wei-Wu He acquired 207,502 shares of the business’s stock in a transaction on Tuesday, September 19th. The shares were acquired at an average price of $1.75 per share, with a total value of $363,128.50. Following the completion of the transaction, the director now owns 513,525 shares in the company, valued at $898,668.75. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 696,329 shares of company stock worth $1,086,138. Insiders own 13.01% of the company’s stock.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.